Theratechnologies Inc. expects to initiate a Phase III trial later this year for ThGRF, a candidate for HIV-associated lipodystrophy. At the same time, the Montreal-based company said it intends to restructure its senior management responsibilities and recruit a new chief executive officer. Luc Tanguay, the firm's current president and CEO, will assume the role of senior executive vice president and chief financial officer once a new CEO is named. (BioWorld Today) Read More
SAN FRANCISCO - Ceremoniously exiting his post atop the Biotechnology Industry Organization, outgoing President Carl Feldbaum delivered a farewell Tuesday at the BIO 2004 International Convention. Read More
